Please note, this OEL/ADE monograph also applies to Isoxsuprine hydrochloride (CAS RN 579-56-6), and Isoxsuprine lactate (CAS RN 58379-21-8). Isoxsuprine is indicated for the treatment of dementia, peripheral vascular disease and Raynaud’s syndrome. Isoxsuprine is a vasodilator that also stimulates beta-adrenergic receptors. It causes direct relaxation of vascular and uterine smooth muscle and its vasodilating action is greater on the arteries supplying skeletal muscles than on those supplying skin.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API).
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL monograph for Isoxsuprine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.